ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464.
from The Medical News http://ift.tt/1z58TKY
from The Medical News http://ift.tt/1z58TKY
No comments:
Post a Comment